Literature DB >> 29595758

Surgical Treatment of Early-Stage Cervical Cancer: A Multi-Institution Experience in 2124 Cases in The Netherlands Over a 30-Year Period.

Marloes Derks, Jacobus van der Velden, Cornelis D de Kroon, Hans W Nijman, Luc R C W van Lonkhuijzen, Ate G J van der Zee, Aeilko H Zwinderman, Gemma G Kenter.   

Abstract

OBJECTIVE: This study aimed to describe the pattern of recurrence and survival related to prognostic variables, including type of surgery as a clinical variable, in patients surgically treated for early cervix cancer.
METHODS: Records of 2124 patients who underwent a radical hysterectomy for International Federation of Gynaecology and Obstetrics stage I/IIA cervical cancer between 1982 and 2011 were reviewed. Clinical-pathologic prognostic variables, also including extent of parametrectomy, were identified and used in a multivariable Cox proportional hazard model to explore associations between disease-free survival (DFS) and prognostic variables.
RESULTS: The 5-year DFS for the total group was 86%. Large tumor diameter, nonsquamous histology, lymph node metastases, parametrial involvement, lymph vascular space invasion, deep stromal invasion, and less radical surgery were independent poor prognostic variables for survival. Disease-free survival was independently associated with the type of radical hysterectomy with pelvic lymphadenectomy in favor of more radical parametrectomy (hazard ratio, 2.0; 95% confidence interval, 1.6-2.5). This difference was not found in tumors with a diameter of at least 20 mm.
CONCLUSIONS: This study confirms that variables such as large tumor diameter, nonsquamous histology, lymph vascular space invasion, deep stromal invasion, positive lymph nodes, and parametrial infiltration are poor prognostic variables in early cervix cancer treated by surgery. The extent of parametrectomy had no influence on survival in tumors of 20 mm or less. For larger tumors, a more radical hysterectomy might be associated with better DFS. Taking into account the possible bias in this study as a result of its retrospective design, ideally a prospective cohort study with clear definition of radicality is necessary to answer this important clinical question.

Entities:  

Mesh:

Year:  2018        PMID: 29595758     DOI: 10.1097/IGC.0000000000001228

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  18 in total

1.  LINC01133 promotes the progression of cervical cancer by sponging miR-4784 to up-regulate AHDC1.

Authors:  Yan Feng; Luyun Qu; Xiuli Wang; Chunyan Liu
Journal:  Cancer Biol Ther       Date:  2019-08-07       Impact factor: 4.742

Review 2.  Human papillomavirus infection, cervical cancer and the less explored role of trace elements.

Authors:  Anne Boyina Sravani; Vivek Ghate; Shaila Lewis
Journal:  Biol Trace Elem Res       Date:  2022-04-25       Impact factor: 3.738

3.  Long non-coding RNA CTBP1-AS2 enhances cervical cancer progression via up-regulation of ZNF217 through sponging miR-3163.

Authors:  Shanshan Yang; Feng Shi; Yuting Du; Zhao Wang; Yue Feng; Jiayu Song; Yunduo Liu; Min Xiao
Journal:  Cancer Cell Int       Date:  2020-07-28       Impact factor: 5.722

4.  Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.

Authors:  Nicolò Bizzarri; Luigi Pedone Anchora; Gian Franco Zannoni; Vittoria Carbone; Matteo Bruno; Camilla Fedele; Valerio Gallotta; Vito Chiantera; Giacomo Avesani; Benedetta Gui; Francesco Fanfani; Anna Fagotti; Giovanni Scambia; Gabriella Ferrandina
Journal:  Br J Cancer       Date:  2021-04-14       Impact factor: 7.640

5.  Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2).

Authors:  Kristyna Nemejcova; Roman Kocian; Christhardt Kohler; Jiri Jarkovsky; Jaroslav Klat; Alberto Berjon; Radovan Pilka; Borek Sehnal; Blanca Gil-Ibanez; Ezequiel Lupo; Almerinda Petiz; Octavio Arencibia Sanchez; Peter Kascak; Fabio Martinelli; Alessandro Buda; Jiri Presl; Marc Barahona; Luc van Lonkhuijzen; Wiktor Szatkowski; Lubos Minar; Maja Pakiz; Pavel Havelka; Cristina Zorrero; Marcin Misiek; Leon Cornelius Snyman; Dariusz Wydra; Ignace Vergote; Alla Vinnytska; Mikulas Redecha; Martin Michal; Solveig Tingulstad; Barbara Kipp; Grzegorz Szewczyk; Robert Toth; Francisco Javier de Santiago Garcia; Pluvio Jesus Coronado Martin; Robert Poka; Karl Tamussino; Mathieu Luyckx; Maxime Fastrez; Juan Carlos Staringer; Anna Germanova; Andrea Plaikner; Sylva Bajsova; Pavel Dundr; Nina Mallmann-Gottschalk; David Cibula
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

6.  Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1.

Authors:  Xing Chen; Dongsheng Xiong; Liya Ye; Kai Wang; Lingfei Huang; Shuangshuang Mei; Jinhong Wu; Shanshan Chen; Xiaoli Lai; Lingzhi Zheng; Meifen Wang
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

7.  Eugenol Exerts Apoptotic Effect and Modulates the Sensitivity of HeLa Cells to Cisplatin and Radiation.

Authors:  Moustafa Fathy; Michael Atef Fawzy; Henning Hintzsche; Toshio Nikaido; Thomas Dandekar; Eman M Othman
Journal:  Molecules       Date:  2019-11-03       Impact factor: 4.411

8.  Minimally invasive surgery for cervical cancer: consequences for treatment after LACC Study.

Authors:  Rainer Kimmig; Thomas Ind
Journal:  J Gynecol Oncol       Date:  2018-05-14       Impact factor: 4.401

9.  Long Noncoding RNA SNHG7, a Molecular Sponge for microRNA-485, Promotes the Aggressive Behavior of Cervical Cancer by Regulating PAK4.

Authors:  Fei Wu; Yujie Sui; Yinhuai Wang; Tianmin Xu; Limei Fan; He Zhu
Journal:  Onco Targets Ther       Date:  2020-01-23       Impact factor: 4.147

10.  LINC00707 Regulates miR-382-5p/VEGFA Pathway to Enhance Cervical Cancer Progression.

Authors:  Hua Guo; Jing Li; Furong Fan; Ping Zhou
Journal:  J Immunol Res       Date:  2021-06-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.